Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Speedel's investigational compound for the treatment of diabetic kidney disease, SPP301, has demonstrated promising efficacy in a phase IIb clinical trial.
Subscribe to our email newsletter
Results from the trial of the compound have shown that it decreases urinary albumin excretion rate (UAER) and total cholesterol in patients with diabetic kidney disease when administered on top of standard treatment.
A total of 286 patients were enrolled in this randomized, placebo controlled trial. It investigated the effects on urinary albumin excretion rate (UAER) of 12-week therapy with varying doses of SPP301 or placebo, administered once daily on top of standard treatment.
Compared to placebo, all doses of SPP301 decreased UAER significantly, with the highest two doses (25mg, 50mg) demonstrating the greatest reduction in UAER. There was also a significant reduction in total cholesterol at all doses compared to placebo.
Diabetic nephropathy represents a large and growing unmet medical need with a high mortality rate affecting an estimated eight million people diagnosed with diabetes in the US, Europe and Japan.
“The compelling results of this trial offer real hope for the treatment of diabetic nephropathy, the leading cause of end stage renal disease, for which treatment options are limited and the mortality rate unacceptably high,” commented professor Rene Wenzel, principal investigator of the phase IIb trial and head of internal medicine at Zell am See Hospital, Austria.
The results from the trial were presented at the 38th annual meeting of the American Society of Nephrology (ASN) in Philadelphia.